

# SEARCH REQUEST FORM

Requestor's Name: \_\_\_\_\_ Serial Number: \_\_\_\_\_  
Date: \_\_\_\_\_ Phone: \_\_\_\_\_ Art Unit: \_\_\_\_\_

## Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

## STAFF USE ONLY

Date completed: <u>05-01-02</u>	Search Site	Vendors
Searcher: <u>Beverly E 4994</u>	<input type="checkbox"/> STIC	<input type="checkbox"/> IG
Terminal time: <u>16</u>	<input type="checkbox"/> CM-1	<input checked="" type="checkbox"/> STN
Elapsed time: _____	<input type="checkbox"/> Pre-S	<input type="checkbox"/> Dialog
CPU time: _____	Type of Search	<input type="checkbox"/> APS
Total time: <u>28</u>	<input type="checkbox"/> N.A. Sequence	<input type="checkbox"/> Geninfo
Number of Searches: _____	<input type="checkbox"/> A.A. Sequence	<input type="checkbox"/> SDC
Number of Databases: <u>1</u>	<input type="checkbox"/> Structure	<input type="checkbox"/> DARC/Questel
	<input type="checkbox"/> Bibliographic	<input type="checkbox"/> Other

09/700057

FILE 'REGISTRY' ENTERED AT 10:31:41 ON 01 MAY 2002

L1 E DEXTRIN/CN 5  
1 S E3  
E DEXTRIN SULPHATE/CN 5  
L2 1 S E2  
E METHYLENE BLUE/CN 5  
L3 1 S E3  
L4 3 S L1 OR L2 OR L3  
E EDTA/CN  
L5 1 S E3  
E SODIUM CITRATE/CN 5  
L6 5 S E3-E7  
L7 6 S L5 OR L6

FILE 'CAPLUS' ENTERED AT 10:33:10 ON 01 MAY 2002

L1 1 SEA FILE=REGISTRY ABB=ON PLU=ON DEXTRIN/CN  
L2 1 SEA FILE=REGISTRY ABB=ON PLU=ON "DEXTRIN SULFATE"/CN  
L3 1 SEA FILE=REGISTRY ABB=ON PLU=ON "METHYLENE BLUE"/CN  
L4 3 SEA FILE=REGISTRY ABB=ON PLU=ON L1 OR L2 OR L3  
L5 1 SEA FILE=REGISTRY ABB=ON PLU=ON EDTA/CN  
L6 5 SEA FILE=REGISTRY ABB=ON PLU=ON ("SODIUM CITRATE"/CN  
OR "SODIUM CITRATE (NA2O7C6H6)"/CN OR "SODIUM CITRATE  
(NA3C6D5O7)"/CN OR "SODIUM CITRATE (NA3C6H5O7)"/CN OR  
"SODIUM CITRATE (NAC6H7O7)"/CN)  
L7 6 SEA FILE=REGISTRY ABB=ON PLU=ON L5 OR L6  
L8 306 SEA FILE=CAPLUS ABB=ON PLU=ON (L4 OR DEXTRIN OR  
METHYLENE BLUE) AND ADHESION  
L9 8 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND (L7 OR (CA OR  
CALCIUM) (W) BIND? (W) AGENT OR EDTA OR EDETTIC OR (NA OR  
SODIUM) (W) CITRATE)

L1 1 SEA FILE=REGISTRY ABB=ON PLU=ON DEXTRIN/CN  
L2 1 SEA FILE=REGISTRY ABB=ON PLU=ON "DEXTRIN SULFATE"/CN  
L3 1 SEA FILE=REGISTRY ABB=ON PLU=ON "METHYLENE BLUE"/CN  
L4 3 SEA FILE=REGISTRY ABB=ON PLU=ON L1 OR L2 OR L3  
L5 1 SEA FILE=REGISTRY ABB=ON PLU=ON EDTA/CN  
L6 5 SEA FILE=REGISTRY ABB=ON PLU=ON ("SODIUM CITRATE"/CN  
OR "SODIUM CITRATE (NA2O7C6H6)"/CN OR "SODIUM CITRATE  
(NA3C6D5O7)"/CN OR "SODIUM CITRATE (NA3C6H5O7)"/CN OR  
"SODIUM CITRATE (NAC6H7O7)"/CN)  
L7 6 SEA FILE=REGISTRY ABB=ON PLU=ON L5 OR L6  
L10 554 SEA FILE=CAPLUS ABB=ON PLU=ON (L4 OR DEXTRIN OR  
METHYLENE BLUE) AND (L7 OR (CA OR CALCIUM) (W) BIND? (W) AGENT  
OR EDTA OR EDETTIC OR (NA OR SODIUM) (W) CITRATE)  
L11 11 SEA FILE=CAPLUS ABB=ON PLU=ON L10 AND (PHOSPHO LIPID  
OR PHOSPHOLIPID OR LUBRICANT)

L12 16 L9 OR L11

L12 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:545500 CAPLUS

DOCUMENT NUMBER: 135:112031

TITLE: Dextrin containing compositions for  
prevention of adhesions

INVENTOR(S): Conroy, Susan

PATENT ASSIGNEE(S): M1 Laboratories Plc, UK

Searcher : Shears 308-4994

09/700057

SOURCE: PCT Int. Appl., 30 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001052866	A1	20010726	WO 2001-GB193	20010119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2363713	A1	20020109	GB 2000-15035	20000621
PRIORITY APPLN. INFO.: GB 2000-1352 A 20000121				
GB 2000-15035 A 20000621				

AB A compn. for the treatment of **adhesions** that are formed as a result of an inflammatory response comprises an aq. formulation contg. the polysaccharide **dextrin** in an effective amt. The invention also discloses a method of treating **adhesions** that are formed as a result of an inflammatory response. Efficacy of 4, 15, and 20% icodextrin in the prevention of **adhesion** in rats was shown.

IT 9004-53-9, **Dextrin**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**dextrin** contg. compns. for prevention of **adhesions**)

IT 60-00-4, **Edta**, biological studies 61-73-4, **Methylene blue** 994-36-5, **Sodium citrate**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**dextrin** contg. compns. for prevention of **adhesions**)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:91416 CAPLUS

DOCUMENT NUMBER: 134:136728

TITLE: Film coatings and film coating compositions based on **dextrin**

INVENTOR(S): Grillo, Susan M.; Korchok, Brian; Kinsey, Bruce; Porter, Stuart C.; Reyes, George; Burke, Thomas J.; Cunningham, Charles

PATENT ASSIGNEE(S): BPSI Holdings, Inc., USA

SOURCE: U.S., 18 pp., Cont.-in-part of U.S. Ser. No. 778,944, abandoned.

Searcher : Shears 308-4994

09/700057

CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6183808	B1	20010206	US 1998-2462	19980102
ZA 9800043	A	19980708	ZA 1998-43	19980105
WO 9830341	A1	19980716	WO 1998-US4124	19980105
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9864454	A1	19980803	AU 1998-64454	19980105
AU 729614	B2	20010208		
BR 9806840	A	20000314	BR 1998-6840	19980105
EP 996508	A1	20000503	EP 1998-910144	19980105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002512601	T2	20020423	JP 1998-531303	19980105
US 6348090	B1	20020219	US 2000-661655	20000914

PRIORITY APPLN. INFO.:

US 1997-778944 B2 19970106  
US 1998-2462 A 19980102  
WO 1998-US4124 W 19980105

AB Disclosed is a dry film coating compn. for forming a coating suspension for film coating nutritional supplements, pharmaceutical tablets, and the like, comprising a **dextrin** and a detackifier. This invention provides a film coating that possesses long-lasting gloss, good film **adhesion**, and good film clarity. A coating soln. was formulated contg. tapioca **dextrin** 70, dextrose 10, mineral oils 10, polyethylene glycol 8, and **Na citrate** 2 %.

IT 9004-53-9, **Dextrin**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (film coating compns. contg. **dextrin** and detackifiers and auxiliary film formers for tablets and nutritional supplements)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:830327 CAPLUS

DOCUMENT NUMBER: 134:21498

TITLE: Article having a transferable breathable skin care composition thereon

INVENTOR(S): Vega, Victor Nicholas; Hanser, Thomas Robert; van Hauwermeiren, Tim; Roe, Donald Carroll

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: U.S., 25 pp.  
CODEN: USXXAM

09/700057

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6153209	A	20001128	US 1999-407950	19990928
WO 2001022933	A1	20010405	WO 2000-US25789	20000920

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-407950 A 19990928

AB The present invention relates to an article having a skin care compn. disposed on at least a portion of the article, e.g. a diaper, training pant, sanitary napkin, pantiliner, incontinence article, and diaper holder. The skin care compn. is a breathable, barrier protectant which can be immobilized on the article and is transferable to the wearer's skin via contact, normal wearer motion and/or body heat. Particularly, the skin care compn. should have a water vapor transmission rate of at least about 0.1 gm/m<sup>2</sup>/h and a barrier property of at least about -25 on Hunter b scale, as measured by a **Methylene Blue** Dye Method. A skin care compn. contg. triglyceride 26, squalane 9, cholesterol hydroxystearate 33, cholesterol 9, petrolatum 12, glyceryl linoleate 7, and sucrose ester fatty acid 4 % was prepd.

IT 60-00-4, Ethylenediamine tetraacetic acid, biological studies

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(articles having transferable breathable skin care compns. contg.)

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:481137 CAPLUS

DOCUMENT NUMBER: 133:61174

TITLE: Concentrated **lubricant** for cooling and protecting and passivating metal surfaces during cutting

INVENTOR(S): Polihroniade, Alfons

PATENT ASSIGNEE(S): S.C. Indpol S.R.L., Bucuresti, Rom.

SOURCE: Rom., 6 pp.  
CODEN: RUXXA3

DOCUMENT TYPE: Patent  
LANGUAGE: Romanian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

Searcher : Shears 308-4994

09/700057

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RO 112758	B1	19971230	RO 1997-164	19970129

AB The metalworking compn. comprises 2-5% soybean oil triglyceride coco amides; 1-25% triethanolamine; 5% ethoxylated nonylphenol; 1% poly(dimethylsiloxane) antifoaming agent; 5% triethanolamine phosphate; 0.2% EDTA; 0.5% refined essential resin oils, e.g., pine oil; 0.1% synthetic dyes, preferably **Methylene Blue**; 2% Na tetraborate; 1% Na silicate; 1% Na molybdate; 2% Na nitrite; 2% Na carbonate; and 0.5% B compd. bactericide. The compn. also contains fatty alcs., poly(ethylene glycol) of mol. wt. 200, textile machine oil, Zn alkyldithiophosphate, chlorinated paraffin, Na benzoate, benzotriazole, mercaptobenzotriazole, Na phosphate, and the balance water. The compns. as prepd. are easy to use, are microorg. resistant, are nonflammable and nontoxic, contain antioxidants and corrosion control agents, and can be used at temps. below 0.degree..

IT 60-00-4, EDTA, uses 61-73-4, **Methylene Blue**  
 RL: TEM (Technical or engineered material use); USES (Uses)  
 (concd. lubricant for cooling and protecting and passivating metal surfaces during cutting)

L12 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1999:736520 CAPLUS  
 DOCUMENT NUMBER: 131:342041  
 TITLE: **Dextrin-containing composition for preventing surgical adhesions**  
 INVENTOR(S): Brown, Colin  
 PATENT ASSIGNEE(S): ML Laboratories PLC, UK  
 SOURCE: PCT Int. Appl., 30 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958168	A1	19991118	WO 1999-GB1306	19990513
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9938336	A1	19991129	AU 1999-38336	19990513
AU 740832	B2	20011115		
BR 9911769	A	20010206	BR 1999-11769	19990513
EP 1085920	A1	20010328	EP 1999-920952	19990513
EP 1085920	B1	20011219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 211002	E	20020115	AT 1999-920952	19990513
NO 2000005492	A	20010112	NO 2000-5492	20001101

Searcher : Shears 308-4994

09/700057

PRIORITY APPLN. INFO.:

GB 1998-10127 A 19980513  
US 1999-272713 A 19990319  
WO 1999-GB1306 W 19990513

AB A method of preventing or reducing the incidence of post-operative **adhesions** in or assocd. with a body cavity, comprises introducing into the body cavity a compn. contg. an aq. soln. or suspension or gel formulation contg. polysaccharide **dextrin**. Preferably, the compn. is allowed to remain in the body cavity for a min. of 2-3 days and esp. over the period during which fibrin exudation is at a max.

IT 60-00-4, EDTA, biological studies 61-73-4,  
Methylene blue 994-36-5,  
Sodium citrate 9004-53-9,  
Dextrin 9004-53-9D, Dextrin, sulfated  
derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(aq. compn. contg. **dextrin** and **Ca-binding agents** and active agents for preventing surgical **adhesions**)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:113540 CAPLUS

DOCUMENT NUMBER: 130:187185

TITLE: Oral pharmaceutical preparation comprising an antiulcer activity compound, and a process for its production

INVENTOR(S): Picornell Darder, Carlos

PATENT ASSIGNEE(S): Intexim, S.A., Spain

SOURCE: PCT Int. Appl., 45 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Spanish

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9906032	A2	19990211	WO 1998-ES204	19980713
WO 9906032	A3	19990812		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
ES 2137862	A1	19991216	ES 1997-1816	19970731
ES 2137862	B1	20000916		
AU 9882173	A1	19990222	AU 1998-82173	19980713
EP 1010423	A2	20000621	EP 1998-932185	19980713
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001511443	T2	20010814	JP 2000-504847	19980713

09/700057

ZA 9806893 A 19990127 ZA 1998-6893 19980731  
ES 2156699 A1 20010701 ES 1999-157 19990127  
ES 2156699 B1 20020301  
NO 2000000435 A 20000323 NO 2000-435 20000127  
PRIORITY APPLN. INFO.: ES 1997-1816 A 19970731  
WO 1998-ES204 W 19980713

OTHER SOURCE(S): MARPAT 130:187185

AB The formulation comprises an inert nucleus and an active layer which is sol. or which disintegrates in water and is obtained from a unique aq. or hydro-alc. soln.-suspension which comprises: an active principle having an antiulcer activity and at least one excipient; and a gastroresistant external coating layer obtained from a soln. which comprises an enteric covering polymer and at least one excipient. The process is carried out by (1) covering the inert nucleus by nebulization of the aq. or hydroalcoholic suspension-soln.; (2) drying the active layer formed during the nebulization of the prior step; and (3) covering the nucleus charged through nebulization with the soln. comprising an enteric coating polymer with at least one excipient to obtain an external gastroresistant coating layer.

IT 994-36-5, Sodium citrate  
9004-53-9, Dextrin

RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(oral pharmaceutical prepn. comprising an antiulcer agent and a process for its prodn.)

L12 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:77458 CAPLUS

DOCUMENT NUMBER: 130:129995

TITLE: Bright white film coatings and film coating compositions therefor

INVENTOR(S): Grillo, Susan M.; Korchok, Brian; Kinsey, Bruce; Hartman, Melanie; Porter, Stuart C.; Steffenino, Rita; Reyes, George; Burke, Thomas J.

PATENT ASSIGNEE(S): Berwind Pharmaceutical Services, Inc., USA

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9903449	A1	19990128	WO 1998-US14830	19980716
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6248391	B1	20010619	US 1997-895484	19970716
AU 9884107	A1	19990210	AU 1998-84107	19980716

Searcher : Shears 308-4994



09/700057

AU 738496 B2 20010920  
EP 1011639 A1 20000628 EP 1998-934621 19980716  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT,  
IE, SI, LT, LV, FI, RO  
BR 9811106 A 20000718 BR 1998-11106 19980716  
JP 2001510149 T2 20010731 JP 2000-502751 19980716  
US 6267808 B1 20010731 US 2001-754937 20010105

PRIORITY APPLN. INFO.:

US 1997-895484 A 19970716  
WO 1998-US14830 W 19980716

AB A dry film coating compn. used to make a bright white film coating for nutritional supplements, pharmaceutical tablets, and the like, comprises dextrose, an auxiliary film-former, and titania. Optionally, but advantageously, the coating compn. also may include one or more of the following components: a plasticizer, a surfactant, a flow aid, and a preservative. The compn. provides a film coating that possesses good film **adhesion** and a smooth surface. A coating dispersion was formulated contg. dextrose 32, HPMC (Pharmacoat E-50) 10, PEG-8000 8, HPMC (Pharmacoat E-15) 5, Na CMC 6, **Na citrate** 3, mineral oil 3, titania 32, and Polysorbate-80 1 %. The dispersion was sprayed onto APAP tablets and this produced a bright white film coating.

IT **68-04-2, Sodium citrate**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preservative; white coating compn. contg. dextrose and film-forming agents and titania for tablets)

IT **9004-53-9, Tapioca dextrin**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(white coating compn. contg. dextrose and film-forming agents and titania for tablets)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:490569 CAPLUS

DOCUMENT NUMBER: 129:137358

TITLE: **Dextrin** film coatings, coating compositions, and their application to vitamins and pharmaceutical tablets

INVENTOR(S): Grillo, Susan M.; Korchok, Brian; Kinsey, Bruce; Porter, Stuart C.; Reyes, George; Burke, Thomas J.; Cunningham, Charles

PATENT ASSIGNEE(S): Berwind Pharmaceutical Services, Inc., USA; BPSI Holdings, Inc.; Grillo, Susan M.; Korchok, Brian; Kinsey, Bruce; Porter, Stuart C.; Reyes, George; Burke, Thomas J.; Cunningham, Charles

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9830341	A1	19980716	WO 1998-US4124	19980105
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP,				

Searcher : Shears 308-4994

09/700057

KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,  
TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,  
TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES,  
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
CI, CM, GA, GN, ML, MR, NE, SN, TD, TG  
US 6183808 B1 20010206 US 1998-2462 19980102  
AU 9864454 A1 19980803 AU 1998-64454 19980105  
AU 729614 B2 20010208  
BR 9806840 A 20000314 BR 1998-6840 19980105  
EP 996508 A1 20000503 EP 1998-910144 19980105  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,  
PT, IE, FI  
JP 2002512601 T2 20020423 JP 1998-531303 19980105  
PRIORITY APPLN. INFO.: US 1997-778944 A2 19970106  
US 1998-2462 A 19980102  
WO 1998-US4124 W 19980105

AB A dry film coating compn. for forming a coating suspension for film  
coating nutritional supplements, pharmaceutical tablets, and the  
like, comprises **dextrin** and a detackifier, such as  
carnauba wax, mineral oil, lecithin, Mg stearate, and acetylated  
monoglyceride. A typical coating compn. comprised tapioca  
**dextrin** 70, dextrose 10, mineral oil 10, polyethylene glycol  
8, and Na citrate 2%.

IT **9004-53-9, Dextrin**  
RL: PRP (Properties); TEM (Technical or engineered material use);  
USES (Uses)  
(**dextrin** film coatings with good gloss, slip,  
**adhesion**, and clarity for vitamins and pharmaceutical  
tablets)

L12 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 1998:207280 CAPLUS  
DOCUMENT NUMBER: 128:275101  
TITLE: Gas and gaseous precursor filled microspheres as  
topical and subcutaneous delivery vehicles  
INVENTOR(S): Unger, Evan C.; Matsunaga, Terry O.; Yellowhair,  
David  
PATENT ASSIGNEE(S): Imarx Pharmaceutical Corp., USA  
SOURCE: U.S., 40 pp. Cont.-in-part of U.S. Ser. No.  
307,305.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 19  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5733572	A	19980331	US 1994-346426	19941129
US 5088499	A	19920218	US 1990-569828	19900820
WO 9109629	A1	19910711	WO 1990-US7500	19901219
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
JP 05502675	T2	19930513	JP 1991-503276	19901219
AT 180170	E	19990615	AT 1991-902857	19901219
ES 2131051	T3	19990716	ES 1991-902857	19901219

Searcher : Shears 308-4994

09/700057

US 5228446 A 19930720 US 1991-717084 19910618  
WO 9222247 A1 19921223 WO 1992-US2615 19920331  
W: AU, CA, JP  
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE  
AU 9220020 A1 19930112 AU 1992-20020 19920331  
AU 667471 B2 19960328  
JP 06508364 T2 19940922 JP 1992-500847 19920331  
EP 616508 A1 19940928 EP 1992-912456 19920331  
EP 616508 B1 20010718  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE  
AT 203148 E 20010815 AT 1992-912456 19920331  
ES 2159280 T3 20011001 ES 1992-912456 19920331  
US 5469854 A 19951128 US 1993-76239 19930611  
US 5580575 A 19961203 US 1993-76250 19930611  
US 5348016 A 19940920 US 1993-88268 19930707  
US 5542935 A 19960806 US 1993-160232 19931130  
US 5585112 A 19961217 US 1993-159687 19931130  
US 5769080 A 19980623 US 1994-199462 19940222  
WO 9428874 A1 19941222 WO 1994-US5633 19940519

W: AU, CA, CN, JP

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT,  
SE

US 5773024 A 19980630 US 1994-307305 19940916  
CA 2177713 AA 19950608 CA 1994-2177713 19941130  
JP 09506098 T2 19970617 JP 1994-515763 19941130  
US 5571497 A 19961105 US 1995-468056 19950606  
CN 1180310 A 19980429 CN 1996-193069 19960327  
US 6001335 A 19991214 US 1996-665719 19960618  
US 5935553 A 19990810 US 1996-758179 19961125  
US 5985246 A 19991116 US 1997-888426 19970708  
AU 713127 B2 19991125 AU 1998-56271 19980224  
AU 9856271 A1 19980507  
AU 9888405 A1 19981203 AU 1998-88405 19981012  
AU 731072 B2 20010322  
AU 9910043 A1 19990304 AU 1999-10043 19990104

PRIORITY APPLN. INFO.:

US 1989-455707 B2 19891222  
US 1990-569828 A2 19900820  
US 1991-716899 B2 19910618  
US 1991-717084 A2 19910618  
US 1993-76239 A2 19930611  
US 1993-76250 A2 19930611  
US 1993-159674 B2 19931130  
US 1993-159687 A2 19931130  
US 1993-160232 A2 19931130  
US 1994-307305 A2 19940916  
WO 1990-US7500 W 19901219  
US 1991-750877 A3 19910826  
US 1992-818069 A3 19920108  
WO 1992-US2615 A 19920331  
US 1992-967974 A3 19921027  
US 1993-17683 A3 19930212  
US 1993-18112 B3 19930217  
US 1993-85608 A3 19930630  
US 1993-88268 A3 19930707  
US 1993-163039 A3 19931206  
US 1994-212553 B2 19940311  
AU 1994-70416 A3 19940519  
US 1994-346426 19941129

09/700057

AU 1995-21850 A3 19941130  
WO 1994-US13817 W 19941130  
US 1995-395683 A3 19950228  
US 1995-468056 A3 19950606  
US 1995-471250 A3 19950606  
US 1996-665719 A3 19960618

AB Gas and gaseous precursor filled microspheres, and foams provide novel topical and s.c. delivery vehicles for various active ingredients, including drugs and cosmetics. Gas and gaseous precursor filled microcapsules were prepd. from dipalmitoylphosphatidylcholine.

IT 60-00-4, Edta, biological studies  
9004-53-9, Dextrin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(gas and gaseous precursor filled microspheres as topical and s.c. delivery vehicles)

L12 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:580666 CAPLUS

DOCUMENT NUMBER: 127:181148

TITLE: Liquid compositions for adrenal cortex function promotion and infection prevention

INVENTOR(S): Sakata, Shigenobu; Tatsumi, Jiro; Fukai, Masaru

PATENT ASSIGNEE(S): Handa, Shigenobu, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09176029	A2	19970708	JP 1995-354770	19951226

AB Liq. compns. for adrenal cortex function promotion and infection prevention comprise Tilia exts. and substances selected from e.g. iron ammonium citrate, salicylic acid and citric acid. The compns. also can be incorporated into cosmetics or foods.

IT 994-36-5, Citric acid sodium salt 9004-53-9,  
Dextrin

RL: BUU (Biological use, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(liq. compns. for adrenal cortex function promotion and infection prevention)

L12 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:351060 CAPLUS

DOCUMENT NUMBER: 125:54579

TITLE: Articular chondrocyte tenascin-C production and assembly into de novo extracellular matrix

AUTHOR(S): Savarese, J. J.; Erickson, H.; Scully, S. P.

CORPORATE SOURCE: Medical Center, Duke University, Durham, NC, 27710, USA

SOURCE: J. Orthop. Res. (1996), 14(2), 273-281

CODEN: JOREDR; ISSN: 0736-0266

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Tenascin-C is an oligomeric glycoprotein of the extracellular matrix

09/700057

that is expressed in a variety of processes including development, tissue remodeling, wound healing, cell **adhesion** /antiadhesion, and cell/matrix interactions. Tenascin has recently been acknowledged as a component of the extracellular matrix of articular cartilage, but its function remains unclear. In this study, bovine articular chondrocytes were grown in alginate beads for 35 days to examine the kinetics of tenascin synthesis and incorporation into de novo extracellular matrix. During the culture period, 6 harvest days were established in which culture medium was recovered, alginate beads were dissocd. with an **EDTA** soln., and chondrocytes were collected and lysed by sonication. Total DNA detn. performed on the cell lysates demonstrated chondrocyte survival and proliferation. Western blotting performed on the medium, **EDTA**/alginate, and lysate samples demonstrated the prodn. of both the 220 and 320 kDa tenascin size variants and their differential compartmentalization within the culture system. Tenascin was incorporated into the alginate bead matrix at a const. rate of 3.8 .mu.g/day. The 320 kDa variant was produced in higher quantity, but the 220 kDa fragment was twice as likely to be incorporated into the de novo matrix. **Methylene blue**/acid fuchsin staining and tenascin immunohistochem. demonstrated the incorporation of tenascin into a progressively expanding matrix surrounding the chondrocytes. The results suggest a role for tenascin in the assembly of the chondrocyte matrix and as a sol. mediator of chondrocytes with possible diverse functions for the tenascin size variants.

L12 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1990:596464 CAPLUS  
DOCUMENT NUMBER: 113:196464  
TITLE: Coating materials for glass fibers  
INVENTOR(S): Forkel, Klaus  
PATENT ASSIGNEE(S): Akademie der Wissenschaften der DDR, Ger. Dem. Rep.  
SOURCE: Ger. (East), 3 pp.  
CODEN: GEXXA8  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	DD 276277	A1	19900221	DD 1987-306163	19870819
AB	The coating materials contain .gtoreq.1 chelating agents and/or chelates in addn. to the usual components, e.g., polymers, <b>adhesion</b> -promoting agents, and <b>lubricants</b> . The coated glass fibers are esp. suitable for the manuf. of reinforced concrete. Glass fibers were coated with an aq. mixt. contg. latex, <b>dextrin</b> , and <b>EDTA</b> -disodium salt. Microscopic investigation of concrete contg. these fibers showed that the glass fiber-cement interphase was essentially calcite-free, in contrast to uncoated glass fibers.				
IT	<b>9004-53-9, Dextrin</b> RL: USES (Uses) (polymer coatings contg. chelates and, for glass fibers for concrete reinforcement)				

Searcher : Shears 308-4994

L12 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1990:97651 CAPLUS  
 DOCUMENT NUMBER: 112:97651  
 TITLE: Introducing model membranes and lipoperoxidation  
 AUTHOR(S): Augusto, Ohara; Carmona-Ribeiro, Ana Maria  
 CORPORATE SOURCE: Dep. Bioquim., Univ. Sao Paulo, Sao Paulo, Brazil  
 SOURCE: Biochem. Educ. (1989), 17(4), 209-10  
 CODEN: BIEDDX; ISSN: 0307-4412  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB A simple and inexpensive lab. expt. is described that provides an easy introduction to both biol. membranes and lipid peroxidn. It also demonstrates 1 of the possible deleterious effects of lipid peroxidn., i.e., an increase in membrane permeability leading to leakage of liposomal contents. The expt. utilizes the incorporation of a chromophore, **methylene blue** (MB), into asolectin liposomes. The entrapment can be visualized and measured by comparing the effects of dialysis on an aq. soln. of MB, and on liposomes prepd. in the same MB soln. After dialysis, the dialyzate liposome MB is submitted to chem. induced lipid peroxidn. along with appropriate controls. Visual examn. as well as quant. measurements provide a clear connection between lipid peroxidn. and increase in MB leakage.

IT **61-73-4, Methylene blue**

RL: MSC (Miscellaneous)

(in lipid peroxidn. in biol. membranes demonstration, lab. expt. in)

IT **60-00-4D, ascorbic acid-iron complexes**

RL: MSC (Miscellaneous)

(lipid peroxidn. induction by, in biol. membranes, lab. expt. in)

L12 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1988:91079 CAPLUS  
 DOCUMENT NUMBER: 108:91079  
 TITLE: Photoelectric effects in bilayer lipid membrane containing metallo-porphyrins and dyes  
 AUTHOR(S): Kutnik, Jan; Tien, H. Ti  
 CORPORATE SOURCE: Dep. Physiol., Michigan State Univ., East Lansing, MI, 48824, USA  
 SOURCE: Photochem. Photobiol. (1987), 46(6), 1009-13  
 CODEN: PHCBAP; ISSN: 0031-8655  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The bilayer lipid membrane (BLM) system contg. metalloporphyrins [tetraphenylporphyrin (TPP)] and dyes as photosensitizers and electron mediators was studied. Cyclic voltammetry was used to det. photocond. and photo-emf of the system. The largest photocond. was obsd. for the Mg-TPP-contg. BLM with Me viologen (MV2+) and I present in the aq. soln. Photoactive dyes, due to their redox ability, caused photovoltage up to 30 mV to develop, but no conductance change was obsd. under illumination in the absence of Mg-TPP. The relevance of cyclic voltammetry to the photoconductance and the photo-emf obsd. in the BLM is discussed.

IT **60-00-4, EDTA, properties 61-73-4,**

**Methylene blue**

RL: PRP (Properties)

(bilayer lipid membrane contg., photoelec. effects in)

09/700057

L12 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1972:31679 CAPLUS  
DOCUMENT NUMBER: 76:31679  
TITLE: Component reactions of oxidative sterol demethylation. Partial purification of a microsomal sterol 4 .alpha.-carboxylic acid decarboxylase  
AUTHOR(S): Rahimtula, Anver D.; Gaylor, James L.  
CORPORATE SOURCE: Sect. Biochem. Mol. Biol., Cornell Univ., Ithaca, N. Y., USA  
SOURCE: J. Biol. Chem. (1972), 247(1), 9-15  
CODEN: JBCHA3  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Partial purification of a NAD<sup>+</sup>-dependent microsomal enzyme that catalyzes decarboxylation of 4.alpha.-carboxylic acids was accomplished. Solubilization was achieved with Na deoxycholate, and the solubilized enzyme was purified free of other enzymes of methyl sterol demethylase by chromatog. on diethyl-aminoethyl-Sephadex A-50. The partially purified enzyme catalyzes decarboxylation of 3.beta.-hydroxy-4.beta.-methyl-5.alpha.-cholest-7-en-4.alpha.-oic acid; approx. equal amts. of CO<sub>2</sub> and 4.alpha.-methyl-5.alpha.-cholest-7-en-3-one are formed. With the 4.beta.-methyl-4.alpha.-carboxylic acid substrate, the enzyme exhibits a K<sub>m</sub> of 7.mu.M and a V<sub>max</sub> of 94.5 nmoles/min/mg of protein. The enzyme is selective for NAD<sup>+</sup>; with NADP<sup>+</sup> the rate is about 5% of the net rate obsd. with NAD<sup>+</sup>. The pH optimum is 9.0; the enzyme is completely inactive in acidic media. Removal of bound phospholipid by treatment with either phospholipase A or C results in no loss of enzymic activity. The enzyme is not inhibited significantly by either EDTA (up to 10mM), CN<sup>-</sup>, Fe<sup>2+</sup>, GSH, Mg<sup>2+</sup>, pregn-4-ene-3,20-dione, 17.beta.-hydroxyandrost-4-en-3-one, androst-4-ene-3,17-dione, isocitrate, or .beta.-hydroxy-butyrate. Zn<sup>2+</sup>, on the other hand, inhibits at concns. between 0.1 and 1.0 mM. Anaerobic conditions result in a 20 to 25% decrease in reaction rate. Under anaerobic conditions, addn. of various electron acceptors, e.g. cytochrome c, **methylene blue**, or K<sub>3</sub>Fe(CN)<sub>6</sub>, did not fully restore activity.

L12 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1963:480541 CAPLUS  
DOCUMENT NUMBER: 59:80541  
ORIGINAL REFERENCE NO.: 59:14946f-g  
TITLE: Bismuth plating on steel from alkaline baths  
AUTHOR(S): McCarthy, J. A.  
CORPORATE SOURCE: U.S. Steel Corp., Monroeville, PA  
SOURCE: Galvanotecnica (1963), 14(5), 89-91  
DOCUMENT TYPE: Journal  
LANGUAGE: Unavailable

AB From plating baths contg. K<sub>4</sub>P<sub>2</sub>O<sub>7</sub>, Na-EDTA, and BiCl<sub>3</sub> at c.d. 0.5-1.5 amp./sq. cm., good Bi coatings directly on steel as base metal are obtained. The pH of the electrolyte must be kept at 9-10; small addns. of dextrin improve the **adhesion** of the coating. The adherent deposit is covered by a gray and (or) dark brown fine powder, which is metallic Bi. The formation of Bi powder can be minimized but not eliminated by operating at 5-15.degree.. After removing the powder by mech. polishing, bright

09/700057

and compact deposits are obtained.

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,  
JICST-EPLUS, JAPIO, CABA, AGRICOLA, VETU, VETB' ENTERED AT 10:37:28  
ON 01 MAY 2002)

L13 8 S L9  
L14 2 S L11  
L15 8 S L13 OR L14  
L16 5 DUP REM L15 (3 DUPLICATES REMOVED)

L16 ANSWER 1 OF 5 WPIDS (C) 2002 THOMSON DERWENT  
ACCESSION NUMBER: 2001-589646 [66] WPIDS  
DOC. NO. CPI: C2001-174785  
TITLE: Composition used for treating **adhesions**  
formed as result of inflammatory response e.g.  
chronic inflammatory conditions comprises aqueous  
formulation of polysaccharide **dextrin**.  
DERWENT CLASS: A96 B04  
INVENTOR(S): CONROY, S  
PATENT ASSIGNEE(S): (MLML-N) ML LAB PLC  
COUNTRY COUNT: 94  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001052866	A1	20010726	(200166)*	EN	30
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2001026926	A	20010731	(200171)		
GB 2363713	A	20020109	(200211)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001052866	A1	WO 2001-GB193	20010119
AU 2001026926	A	AU 2001-26926	20010119
GB 2363713	A	GB 2000-15035	20000621

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001026926	A Based on	WO 200152866

PRIORITY APPLN. INFO: GB 2000-15035. 20000621; GB 2000-1352  
20000121

AN 2001-589646 [66] WPIDS  
AB WO 200152866 A UPAB: 20011113  
NOVELTY - Composition comprises an aqueous formulation containing a  
polysaccharide **dextrin**.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the  
following:



(1) a biocompatible, bioresorbable, non-toxic **adhesion** prevention kit for preventing or reducing the incidence of **adhesions** in mammals comprises the aqueous formulation; and  
 (2) products containing the aqueous formulation as a combined preparation for preventing or reducing the incidence of **adhesions**.

USE - Used for the treatment of **adhesions** formed as a result of an inflammatory response, other than post-operative **adhesions**, and for preventing or reducing the incidence or **adhesions** in or associated with a body cavity such as peritoneum, pericardium or plura and synovial cavities such as joints and tendons in humans or animals. The inflammatory response includes chronic inflammatory conditions such as pelvic inflammatory disease, arthritis, chronic inflammatory bowel disease, ulcerative colitis, Crohn's disease, irritable bowel syndrome and/or acute inflammatory conditions such as those induced by tissue injury, which is as a result of chemical insult.

ADVANTAGE - The composition has a good shelf life. The **dextrin** is non-toxic, cheap and holds fluid in a body cavity and can also be readily metabolized within the body. It does not provide any undesired side effects or dependency.  
 Dwg.0/3

L16 ANSWER 2 OF 5 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 ACCESSION NUMBER: 2001343944 EMBASE  
 TITLE: Reduction of post-operative peritoneal **adhesions** using **methylene blue**.  
 AUTHOR: Izadpanah A.; Payravi S.A.A.  
 CORPORATE SOURCE: Dr. A. Izadpanah, Dept. of General Surgery, Shiraz Univ. of Medical Sciences, P.O. Box: 71345-1853, Shiraz, Iran (Islamic Republic of).  
 izadpana@sums.ac.ir  
 SOURCE: Iranian Journal of Medical Sciences, (2001) 26/1-2 (51-54).  
 Refs: 14  
 ISSN: 0253-0716 CODEN: IJMSDW  
 COUNTRY: Iran (Islamic Republic of)  
 DOCUMENT TYPE: Journal; Article  
 FILE SEGMENT: 009 Surgery  
 037 Drug Literature Index  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English  
 AB Background/Objective: Postoperative peritoneal **adhesion** bands (PABs) are one of the most common complications of laparotomies. Approximately two - third of all intestinal obstructions are caused by **adhesion** bands. The use of **methylene blue** (MB) for prevention of these **adhesions** has been postulated on account of inhibitory effect of MB on oxygen for the transfer of electrons from flavo-enzymes primarily xantine oxidase. Methods: In this study 6 groups of guinea pigs (n=20 in each group), laparotomy and induction of **adhesion** was performed in, then MB was administered intraperitoneally, at 0.5, 1, 5, 10 or 20 mg/kg to experimental groups. Control group did not receive MB. After 2 weeks they were sacrificed and their PABs was graded by Nair classification. Results: MB at 0.5 mg/kg reduced the formation and severity of PABs significantly (P<0.005). However, at 1 and 5 mg/kg the PABs were not

09/700057

reduced ( $P < 0.306$  for G3 and  $P < 0.219$  for G4). At high doses of 10 and 20 mg/kg MB was lethal to 80% and 100% of the animals, respectively. Conclusion: In conclusion, MB might be able to prevent PABs at low dose (0.5 mg/kg) in guinea pigs. However, at high doses (gtoreq. mg/kg) it was lethal.

L16 ANSWER 3 OF 5 WPIDS (C) 2002 THOMSON DERWENT  
ACCESSION NUMBER: 2000-038967 [03] WPIDS  
DOC. NO. NON-CPI: N2000-029373  
DOC. NO. CPI: C2000-010069  
TITLE: Prevention or reduction of surgical  
adhesions in body cavities.  
DERWENT CLASS: B04 D22 P34  
INVENTOR(S): BROWN, C  
PATENT ASSIGNEE(S): (MLML-N) ML LAB PLC  
COUNTRY COUNT: 87  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9958168	A1	19991118	(200003)*	EN	29
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC					
MW NL OA PT SD SE SL SZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES					
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK					
LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG					
SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW					
AU 9938336	A	19991129	(200018)		
BR 9911769	A	20010206	(200111)		
NO 2000005492	A	20010112	(200115)		
EP 1085920	A1	20010328	(200118)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
CN 1300226	A	20010620	(200159)		
AU 740832	B	20011115	(200202)		
EP 1085920	B1	20011219	(200206)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
DE 69900648	E	20020131	(200216)		
ES 2165735	T3	20020316	(200227)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9958168	A1	WO 1999-GB1306	19990513
AU 9938336	A	AU 1999-38336	19990513
BR 9911769	A	BR 1999-11769	19990513
		WO 1999-GB1306	19990513
NO 2000005492	A	WO 1999-GB1306	19990513
		NO 2000-5492	20001101
EP 1085920	A1	EP 1999-920952	19990513
		WO 1999-GB1306	19990513
CN 1300226	A	CN 1999-806083	19990513
AU 740832	B	AU 1999-38336	19990513
EP 1085920	B1	EP 1999-920952	19990513
		WO 1999-GB1306	19990513
DE 69900648	E	DE 1999-600648	19990513
		EP 1999-920952	19990513
		WO 1999-GB1306	19990513

09/700057

ES 2165735 T3

EP 1999-920952 19990513

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9938336	A	Based on	WO 9958168
BR 9911769	A	Based on	WO 9958168
EP 1085920	A1	Based on	WO 9958168
AU 740832	B	Previous Publ.	AU 9938336
		Based on	WO 9958168
EP 1085920	B1	Based on	WO 9958168
DE 69900648	E	Based on	EP 1085920
		Based on	WO 9958168
ES 2165735	T3	Based on	EP 1085920

PRIORITY APPLN. INFO: US 1999-272713 19990319; GB 1998-10127  
19980513

AN 2000-038967 [03] WPIDS

AB WO 9958168 A UPAB: 20000118

NOVELTY - Composition containing the polysaccharide **dextrin** in an aqueous formulation to prevent or reduce the incidence of post-operative **adhesions** in or associated with a body cavity.

USE - The product is used as stated, to prevent or reduce the risk of post-operative **adhesions** in body cavities, including the peritoneum, pericardium, pleura, and synovial cavities for joints and tendons, notably the peritoneum, also for possible **adhesions** after spinal and cranial surgery. For these purposes, the product is conveniently packaged as a kit for surgical use in humans (or other animals) containing the **dextrin** or derivative as a solution, suspension, or gel.

ADVANTAGE - The **dextrin** is easily water soluble, with good biocompatibility, is metabolizable, and does not cause immunological hypersensitivity, in contrast to prior art dextran used for these purposes. The method is also superior to patch application in the form of films.

Dwg.0/0

L16 ANSWER 4 OF 5 MEDLINE DUPLICATE 1  
ACCESSION NUMBER: 96218870 MEDLINE  
DOCUMENT NUMBER: 96218870 PubMed ID: 8648506  
TITLE: Articular chondrocyte tenascin-C production and assembly into de novo extracellular matrix.  
AUTHOR: Savarese J J; Erickson H; Scully S P  
CORPORATE SOURCE: Orthopedic Cell Biology Laboratory, Duke University Medical Center, Durham, North Carolina 27710, USA.  
SOURCE: JOURNAL OF ORTHOPAEDIC RESEARCH, (1996 Mar) 14 (2) 273-81.  
Journal code: JIQ; 8404726. ISSN: 0736-0266.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199607  
ENTRY DATE: Entered STN: 19960805  
Last Updated on STN: 19960805  
Entered Medline: 19960725

Searcher : Shears 308-4994

09/700057

AB Tenascin-C is an oligomeric glycoprotein of the extracellular matrix that is expressed in a variety of processes including development, tissue remodeling, wound healing, cell **adhesion** /antiadhesion, and cell/matrix interactions. Tenascin has recently been acknowledged as a component of the extracellular matrix of articular cartilage, but its function remains unclear. In this study, bovine articular chondrocytes were grown in alginate beads for 35 days to examine the kinetics of tenascin synthesis and incorporation into de novo extracellular matrix. During the culture period, 6 harvest days were established in which culture medium was recovered, alginate beads were dissociated with an **EDTA** solution, and chondrocytes were collected and lysed by sonication. Total DNA determination performed on the cell lysates demonstrated chondrocyte survival and proliferation. Western blotting performed on the medium, **EDTA**/alginate, and lysate samples demonstrated the production of both the 220 and 320 kDa tenascin size variants and their differential compartmentalization within the culture system. Tenascin was incorporated into the alginate bead matrix at a constant rate of 3.8 micrograms/day. The 320 kDa variant was produced in higher quantity, but the 220 kDa fragment was twice as likely to be incorporated into the de novo matrix. **Methylene blue**/acid fuchsin staining and tenascin immunohistochemistry demonstrated the incorporation of tenascin into a progressively expanding matrix surrounding the chondrocytes. The results suggest a role for tenascin in the assembly of the chondrocyte matrix and as a soluble mediator of chondrocytes with possible diverse functions for the tenascin size variants.

L16 ANSWER 5 OF 5 WPIDS (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: 1984-211153 [34] WPIDS

DOC. NO. CPI: C1984-088845

TITLE: Surface finished steel sheet prodn. - involves applying zinc composite plating layer using bath contg. cobalt ions and positively charged alumina sol..

DERWENT CLASS: E16 E17 E37 M11

PATENT ASSIGNEE(S): (KAWI) KAWASAKI STEEL CORP

COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 59123796	A	19840717	(198434)*		4

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 59123796	A	JP 1982-233878	19821228

PRIORITY APPLN. INFO: JP 1982-233878 19821228

AN 1984-211153 [34] WPIDS

AB JP 59123796 A UPAB: 19930925

Steel sheet is produced by applying a Zn composite plating layer onto surface of a steel sheet from a Zn plating bath contg. 0.001-0.5 mol/l of Co ion and 1-200 g/l of positively charged alumina sol (alumina content 20wt.%).

Searcher : Shears 308-4994

09/700057

The Zn plating bath pref. contains Zn chloride as the major component, and opt. pH buffer agent such as boric acid or phosphate etc., electroconductive agent such as ammonium chloride or K chloride etc., complexing agent such as citric acid, tartaric acid or EDTA etc. or brightener such as acrylamide or dextrin, etc.

USE/ADVANTAGE - The obtd. sheet shows excellent corrosion resistance, **adhesion** to paint and weldability, and it is suitable for automobile parts, electric appliance parts or construction material, etc.

0/2

FILE 'CAPEUS' ENTERED AT 10:40:53 ON 01 MAY 2002

- L17 7 SEA ABB=ON PLU=ON (MB(S)METHYLENE) AND (L7 OR (CA OR CALCIUM) (W)BIND?(W)AGENT OR EDTA OR EDETIC OR (NA OR SODIUM) (W)CITRATE)
- L18 1 SEA ABB=ON PLU=ON L17 AND (PHOSPHO LIPID OR PHOSPHOLIPI D OR LUBRICANT)
- L19 0 SEA ABB=ON PLU=ON (MB(S)METHYLENE AND ADHESION) AND (L7 OR (CA OR CALCIUM) (W)BIND?(W)AGENT OR EDTA OR EDETIC OR (NA OR SODIUM) (W)CITRATE)
- L20 0 SEA ABB=ON PLU=ON L18 NOT L12

FILE 'MEDLINE', BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO, CABA, AGRICOLA, VETU, VETB' ENTERED AT 10:43:54 ON 01 MAY 2002

- L21 0 SEA ABB=ON PLU=ON L18
- L22 1 SEA ABB=ON PLU=ON L19
- L23 0 SEA ABB=ON PLU=ON L22 NOT L15

(FILE 'MEDLINE' ENTERED AT 10:46:32 ON 01 MAY 2002)

- L24 553 SEA FILE=MEDLINE ABB=ON PLU=ON DEXTRINS/CT
- L25 18142 SEA FILE=MEDLINE ABB=ON PLU=ON "EDETIC ACID"/CT
- L26 11060 SEA FILE=MEDLINE ABB=ON PLU=ON CITRATES/CT
- L27 1 SEA FILE=MEDLINE ABB=ON PLU=ON L24 AND (L25 OR L26)

- L24 553 SEA FILE=MEDLINE ABB=ON PLU=ON DEXTRINS/CT
- L28 6238 SEA FILE=MEDLINE ABB=ON PLU=ON ADHESIONS/CT
- L29 0 SEA FILE=MEDLINE ABB=ON PLU=ON L24 AND L28

L27 ANSWER 1 OF 1 MEDLINE

AN 2000211901 MEDLINE

TI Properties and stability of glycerophosphate oxidase isolated from a mutant strain of Aerococcus viridans.

AU MacKova M; Kost'Al J; Demnerova K

SO LETTERS IN APPLIED MICROBIOLOGY, (2000 Mar) 30 (3) 188-91.  
Journal code: AL0; 8510094. ISSN: 0266-8254.

AB The properties of microbial L-alpha-glycerophosphate oxidase (GPO) isolated from a mutant strain of Aerococcus viridans DBM 1509 were estimated. The stability at different temperatures and pH were detected. At 4 degrees C the enzyme lost activity during 15 d, at 20 degrees C and 30 degrees C GPO activity decreased during 30 and 25 h, respectively. The highest stability was measured at - 20 degrees C and pH 9. At 4 degrees C the stability was enhanced by the addition of 0.1 M EDTA or by lyophilization in the presence of dextrin. These conditions allow the prolongation of the low stability of microbial GPO which limited its use, and give the

09/700057

opportunity to increase the stability of other enzymes

FILE 'HOME' ENTERED AT 10:47:53 ON 01 MAY 2002

Searcher : Shears 308-4994